Literature DB >> 21895038

A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Patrick Poulin1.   

Abstract

BACKGROUND AND OBJECTIVES: Existing methods for the prediction of human clearance of therapeutic proteins involve the use of allometry approaches. In general, these approaches have concentrated on the role of body weight, with only occasional attention given to more specific physiological parameters. The objective of this study was to develop a mechanism-based model of hepatic clearance (CL(H)), which combines a single-species scaling approach with liver physiology, for predicting CL(H) of selected glycoprotein derivate therapeutics, and to compare the outcome of this novel method with those of two empirical methods obtained from the literature - namely, the single-exponent theory and multiple-species allometry. Thus, this study was designed as an explanatory study to verify if the addition of physiological information is of benefit for extrapolating clearance of selected therapeutic proteins from one species to another.
METHODS: Five glycoprotein derivate therapeutics that are known to be principally eliminated by asialoglycoprotein receptors (ASGPRs) under in vivo conditions were selected. It was assumed that the interspecies differences in CL(H) reported for these compounds are reflected by the interspecies differences in the abundance of these receptors. Therefore, key scaling factors related to these differences were integrated into one model. Fourteen extrapolation (prediction) scenarios across species were used in this study while comparing the single-species model, based on physiology, with the single-exponent theory. In addition, the physiological model was compared with multiple-species allometry for three proteins.
RESULTS: In general, the novel physiological model is superior to the derived allometric methods. Overall, the physiological model produced a predicted CL(H) value with levels of accuracy of 100% within 3-fold, 100% within 2-fold and about 82% within 1.5-fold, compared with the observed values, whereas the levels of accuracy decreased to 93%, 77% and 53%, respectively, for allometry. The proposed physiological model is also superior to allometry on the basis of the root mean square error and absolute average fold error values.
CONCLUSIONS: It has been demonstrated that interspecies differences in the abundance of ASGPRs principally govern interspecies variations in CL(H) of compounds that are principally eliminated by ASGPRs. Overall, the proposed physiological model is an additional tool, which should facilitate investigation and prediction of human CL(H) of specific glycoproteins solely on the basis of clearance data determined in a single preclinical species.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21895038     DOI: 10.2165/11592610-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  34 in total

1.  Interspecies prediction of human drug clearance based on scaling data from one or two animal species.

Authors:  Huadong Tang; Azher Hussain; Mauricio Leal; Michael Mayersohn; Eric Fluhler
Journal:  Drug Metab Dispos       Date:  2007-07-23       Impact factor: 3.922

2.  Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents.

Authors:  Kazumi Komoriya; Yukio Kato; Yujiro Hayashi; Kazuhiro Ohsuye; Ryuichiro Nishigaki; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-12-18       Impact factor: 3.922

3.  Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements.

Authors:  Anna-Karin Sohlenius-Sternbeck
Journal:  Toxicol In Vitro       Date:  2006-06-29       Impact factor: 3.500

4.  Comparative determination of the asialoglycoprotein receptor by ligand and antibody binding in hepatocytes from normal and diabetic rats.

Authors:  A Slama; H Zinbi; J Feger; M Dodeur
Journal:  Biol Cell       Date:  1988       Impact factor: 4.458

Review 5.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

6.  Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation.

Authors:  Iftekhar Mahmood
Journal:  J Pharm Sci       Date:  2009-10       Impact factor: 3.534

Review 7.  Interspecies scaling of therapeutic monoclonal antibodies: initial look.

Authors:  Jie Ling; Honghui Zhou; Qun Jiao; Hugh M Davis
Journal:  J Clin Pharmacol       Date:  2009-10-16       Impact factor: 3.126

8.  Glucocorticoid hepatopathy: effect on receptor-mediated endocytosis of asialoglycoproteins.

Authors:  M S Kuhlenschmidt; W E Hoffmann; M K Rippy
Journal:  Biochem Med Metab Biol       Date:  1991-10

9.  Asialoorosomucoid degradation by normal and diabetic rat hepatocytes.

Authors:  M Dodeur; S Coumoul; P Scarmato; G Durand; J Feger; J Agneray
Journal:  Eur J Biochem       Date:  1984-05-02

Review 10.  Pharmacokinetic allometric scaling of coagulation factors and tissue-type plasminogen activators.

Authors:  I Mahmood
Journal:  Haemophilia       Date:  2009-06-11       Impact factor: 4.287

View more
  5 in total

Review 1.  Follicle-Stimulating Hormone Glycobiology.

Authors:  George R Bousfield; David J Harvey
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

Review 2.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

3.  Comparative pharmacology of a new recombinant FSH expressed by a human cell line.

Authors:  Wolfgang Koechling; Daniel Plaksin; Glenn E Croston; Janni V Jeppesen; Kirsten T Macklon; Claus Yding Andersen
Journal:  Endocr Connect       Date:  2017-04-27       Impact factor: 3.335

Review 4.  New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect.

Authors:  James A Dias; Alfredo Ulloa-Aguirre
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

5.  Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients.

Authors:  Bernd Meibohm
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.